Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05978141 · ClinicalTrials.gov registry record
A Registry for People With T-cell Lymphoma
A clinical trial of T-Cell Lymphoma and T-cell-prolymphocytic Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT05978141 is a study of T-Cell Lymphoma and T-cell-prolymphocytic Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,000 participants, above the 68-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (1371% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05978141, a study of T-Cell Lymphoma and T-cell-prolymphocytic Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Conditions Studied
Interventions
- OTHER Optional Blood Sample and Nail Sample
Study Locations (20)
California
- City of Hope Cancer Center (Data collection only) - Duarte
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only) - San Diego
- University of California San Francisco (Data collection only) - San Francisco
- Stanford University Medical Center (Data collection only) - Stanford
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) - Commack
- Memorial Sloan Kettering Westchester (All protocol activities) - Harrison
- Weill Cornell Medical Center (Data Collection Only) - New York
Florida
- University of Miami (Data Collection Only) - Miami
- Moffitt Cancer Center (Data Collection Only) - Tampa
Massachusetts
- Massachusetts General Hospital (Data Collection Only) - Boston
- Dana Farber Cancer Institute (Data Collection Only) - Boston
New Jersey
- Memorial Sloan Kettering at Basking Ridge (All protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
Colorado
- University of Colorado (Data Collection Only) - Aurora
Connecticut
- Yale University (Data Collection Only) - New Haven
Georgia
- Emory University (Data Collection Only) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2030-07-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05978141
The ClinicalTrials.gov registry entry for NCT05978141 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 68-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (1371% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Optional Blood Sample and Nail Sample is the first listed.
NCT05978141 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT05978141 about?
NCT05978141 is a clinical study titled "A Registry for People With T-cell Lymphoma". The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
What is the current status of trial NCT05978141?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2023-07-27. Estimated completion is 2030-07-27.
What conditions does trial NCT05978141 study?
This clinical trial studies the following conditions: T-Cell Lymphoma, T-cell-prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, NK-Cell Lymphoma, Aggressive NK-cell Leukemia.
What interventions are being tested in trial NCT05978141?
The interventions under investigation include: Optional Blood Sample and Nail Sample (OTHER).
Who is sponsoring clinical trial NCT05978141?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05978141 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RECRUITING · Phase 2
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
Study of Tazemetostat in Lymphoid Malignancies
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.